Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 9/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | NOS1 | P29475 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 2/20 | 0.39 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.39 |
| ▸ | TSPO | P30536 | 1/20 | 0.38 |
| ▸ | KLK1 | P06870 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL562921 | 0.92 | KCNH2 (0.41) | TLR7MAPTRXFP1NOS1KMT2A | |
| SCHEMBL561914 | 0.91 | TLR7 (0.39) | TLR7NOS1KMT2AALDH1A1HTT | |
| SCHEMBL562667 | 0.87 | TLR7 (0.43) | TLR7MAPTNOS1KMT2ATSPO | |
| SCHEMBL562449 | 0.85 | TLR7 (0.40) | TLR7MAPTRXFP1NOS1TP53 | |
| SCHEMBL561529 | 0.83 | TP53 (0.38) | TLR7NOS1TP53 | |
| SCHEMBL562256 | 0.82 | KCNH2 (0.37) | TLR7 | |
| SCHEMBL563312 | 0.78 | DYRK1A (0.43) | MAPTKMT2AALDH1A1 | |
| SCHEMBL563045 | 0.77 | TLR7 (0.72) | TLR7 | |
| SCHEMBL3339558 | 0.76 | SLC2A1 (0.42) | KMT2AALDH1A1TP53HPGDHTT | |
| SCHEMBL563162 | 0.72 | PTGS2 (0.33) | NOS1TSPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120035209-A1 | Hydroxy Substituted 1H-Imidazopyridines and Methods | PFIZER INC. (US) | 2012-02-09 | — | — | US | disclosed |
| US-20100152230-A1 | HYDROXY SUBSTITUTED 1H-IMIDAZOPYRIDINES AND METHODS | PFIZER INC. | 2010-06-17 | — | — | US | disclosed |
| EP-1924581-A1 | HYDROXY SUBSTITUTED 1H-IMIDAZOPYRIDINES AND METHODS | Pfizer, Inc. (US) | 2008-05-28 | — | — | EP | disclosed |
| WO-2007028129-A1 | HYDROXY SUBSTITUTED 1H-IMIDAZOPYRIDINES AND METHODS | PFIZER INC. (US) | 2007-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152230-A1 | HYDROXY SUBSTITUTED 1H-IMIDAZOPYRIDINES AND METHODS | IL4, IL2, IL4I1 | TLR7 210/4885MAPT 4506/4885RXFP1 3321/4885 |
| US-20120035209-A1 | Hydroxy Substituted 1H-Imidazopyridines and Methods | IL2, IL4, IL4I1 | TLR7 231/4885MAPT 4506/4885RXFP1 3435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.